Latest stories on SLN
Silence Therapeutics to Participate in Three September Investor Conferences
StockTitan56 · neutralgeneral
Warsh’s Silence Could Be Louder Than Marvell’s Earnings
Barron's48 · neutralgeneral
At Jackson Hole, Silence May Not Be Golden
Yahoo Finance42 · neutralgeneral
Silence Therapeutics: Making Some Recent Noise
Seeking Alpha63 · neutralproduct/pr
Silence Therapeutics plc (SLNCF) files 8-K
SEC 8-K50 · neutralgeneral
Silence Therapeutics Prices $175 Million Upsized Offering to Advance siRNA Therapies
August 12, 2026
MarketChameleon24 · bearishgeneral
Why is Silence Therapeutics stock sliding today?
Investing.com Markets42 · neutralgeneral
Silence Therapeutics prices upsized $175M ADS offering at $13.50 each
Seeking Alpha24 · bearishgeneral
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
StockTitan28 · bearishgeneral
Morgan Stanley maintains Overweight rating on Silence Therapeutics
Seeking Alpha67 · bullishanalyst
Silence Therapeutics price target raised to $32 from $25 at Morgan Stanley
The Fly61 · neutralanalyst
At a glance: stocks gapping up premarket
Seeking Alpha63 · neutralgeneral
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript
Seeking Alpha56 · neutralproduct/pr
Silence Therapeutics Files To Sell 150m In Adss
The Fly28 · bearishgeneral
Silence Therapeutics launches $150M ADS offering
Seeking Alpha28 · bearishgeneral
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
StockTitan24 · bearishgeneral
Silence Therapeutics stock surges as divesiran trial results fuel optimism
Seeking Alpha73 · bullishproduct/pr
SLN’s Q2 2026 Results: Advancing siRNA Therapies and Trimming Losses Amid R&D Progress
August 10, 2026
MarketChameleon63 · neutralearnings
Silence Announces Results From Phase 2 Sanreco Trial Met Primary Endpoint
The Fly67 · bullishproduct/pr
At a glance: stocks gapping up premarket
Seeking Alpha63 · neutralgeneral
Silence Therapeutics plc (SLNCF) files 8-K
SEC 8-K50 · neutralgeneral
Silence Therapeutics GAAP EPS of -$0.09 beats by $0.08
Seeking Alpha56 · neutralearnings
Silence Therapeutics Schedules Conference to Reveal Phase 2 SANRECO Data on Divesiran in Polycythemia Vera
August 10, 2026
MarketChameleon67 · bullishproduct/pr